Abstract WMP97: Symptomatic Steno-occlusion Of Major Cerebral Arteries And Stroke Recurrence In Acute Ischemic Stroke Patients With Atrial Fibrillation

Media type: E-Article
Title: Abstract WMP97: Symptomatic Steno-occlusion Of Major Cerebral Arteries And Stroke Recurrence In Acute Ischemic Stroke Patients With Atrial Fibrillation
Contributor: Guk, Hyung Seok; Kim, Do Yeon; Hong, Keun-Sik; Kim, Jun Yup; Kang, Jihoon; Kim, Beom J; Han, Moon Ku; Choi, Kang-Ho; Kim, Joon-Tae; Park, Man Seok; Yum, Kyu Sun; Shin, Dong-Ick; Gwak, Dong-Seok; Kim, Dong-Eog; Kim, Yong Soo; Kang, Kyusik; Kim, Jae G; Lee, Soo Joo; Lee, Minwoo; Oh, Mi-Sun; Yu, Kyung-Ho; Lee, Byung-Chul; Park, Hong-Kyun; Cho, Yong-Jin; [...]
Published: Ovid Technologies (Wolters Kluwer Health), 2023
Published in: Stroke, 54 (2023) Suppl_1
Language: English
DOI: 10.1161/str.54.suppl_1.wmp97
ISSN: 0039-2499; 1524-4628
Keywords: Advanced and Specialized Nursing ; Cardiology and Cardiovascular Medicine ; Neurology (clinical)
Origination:
Footnote:
Description: <jats:p> <jats:bold>Introduction:</jats:bold> There is lack of knowledge on whether symptomatic steno-occlusion (SYSO), common in acute ischemic stroke (AIS) patients with atrial fibrillation (AF), could increase the long-term risk of stroke recurrence in these patients. </jats:p> <jats:p> <jats:bold>Methods:</jats:bold> From a prospective cohort of patients with AIS and AF enrolled in 14 centers between Oct 2017 and Dec 2018, we identified patients who underwent MR angiography during hospitalization and completed 3-year follow-up including death during follow-up. SYSO was defined as (1) <jats:italic>≥</jats:italic> 50% stenosis or occlusion of cerebral arteries relevant to acute infarction or (2) any residual stenosis after endovascular treatment. Using cause-specific hazard models with non-stroke death as a competing risk, the risk of any recurrent stroke and recurrent ischemic stroke was estimated according to SYSO, respectively. </jats:p> <jats:p> <jats:bold>Results:</jats:bold> A total of 889 patients (mean age, 74.4 years; men, 54.6 %; median NIHSS, 6) were analyzed for this study. During the median 1096 days of follow-up, 152 any recurrent strokes, 142 recurrent ischemic strokes, and 208 deaths were observed. Patients with SYSO, compared to those without, were more likely to be older, be female, have hypertension, diabetes and history of stroke/TIA, and be on antiplatelets at discharge and were less likely to be on anticoagulants at discharge ( <jats:italic>p</jats:italic> <.05). The cumulative incidence of recurrent stroke in patients with and without SYSO was 25.2% and 8.3% at 1 month, 33.1% and 9.9% at 1 year, and 41.8% and 13.1% at 3 years, respectively ( <jats:italic>p</jats:italic> <.001). With adjusting age, sex, hypertension, diabetes, history of stroke/TIA, discharge antiplatelets, and discharge anticoagulants, SYSO increased the risk of any stroke recurrence (adjusted hazard ratio [95% confidence interval]; 3.02 [2.18-4.20]; <jats:italic>p</jats:italic> <.001) and ischemic stroke recurrence (3.20 [2.28-4.51]; <jats:italic>p</jats:italic> <.001). </jats:p> <jats:p> <jats:bold>Conclusions:</jats:bold> SYSO in AIS patients with AF substantially increased the risk of recurrent stroke by a 3-fold or more. Accordingly, SYSO should be considered in stratifying the risk of recurrence in AIS patients with AF. </jats:p>
Access State: Open Access

Search in field:

Recently searched for: